Rocco,
Good question. The primary objective of the trial is to show that the addition of PPG to patients with chronic kidney disease who are taking the approved drug, irbesartan, is safe of the treatment period. A secondary objective is to show that this addition results in a reduction in proteinuria. In my opinion, a reduction of 20% or greater is required as a minimum. However, given the mix of aetiologies of chronic kidney disease in the study and variability between patients, I do not expect all patients to show a reduction of this amount. I would like to see a majority of patients show this reduction. If we see a greater reduction than this in some patients, then this would be very positive, as it further validates the approach of combining a ARB with a CCR2 antagonist.
hope that helps,
A.
Rocco, Good question. The primary objective of the trial is to...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.025(5.62%) |
Mkt cap ! $231.2M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 44.0¢ | 41.8¢ | $1.239M | 2.905M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 257588 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |